BioTuesdays

Author - Stephen Kilmer

Affimed

Stifel starts Affimed at buy; PT $12

Stifel launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and price target of $12. The stock closed at $5.85 on Sept. 29. Affimed is a clinical-stage biotechnology company focused on bispecific antibody...

Clarus-Therapeutics

Maxim starts Clarus Therapeutics at buy; PT $13

Maxim Group initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with a “buy” rating and $13 price target. The stock closed at $5.61 on Sept. 28. Clarus is a commercial-stage company marketing Jatenzo, an oral...

Stifel starts Repare Therapeutics at buy; PT $48

Stifel launched coverage of Repare Therapeutics (NASDAQ:RPTX) with a “buy” rating and $48 price target. The stock finished at $28.48 on Sept. 22. Analyst Benjamin Burnett, Ph.D., writes that his rating is largely...

Kinnate-Biopharma

Stifel starts Kinnate Biopharma at buy; PT $32

Stifel launched coverage of Kinnate Biopharma (NASDAQ:KNTE) with a “buy” rating and $32 price target. The stock closed at $23.44 on Sept. 22. “Our positive thesis is based on the belief that the Phase 1 data for KIN...

Eargo

WB cuts Eargo to market perform

William Blair downgraded Eargo (NASDAQ:EAR), a maker of hearing aids,  to “market perform” after the company’s 8K stated that an audit by the company’s largest third-party payer was being turned over to the U...

Annexon-biosciences

Cantor starts Annexon at OW; PT $40

Cantor Fitzgerald initiated coverage of Annexon (NASDAQ:ANNX) with an “overweight” rating and $40 price target. The stock closed at $21.12 on Sept. 22. Annexon is a platform-enabled therapeutics company focused on...

IceCure

AGP starts IceCure Medical at buy; PT $14.50

Alliance Global Partners launched coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $14.50. The stock closed at $8.61 on Sept. 21. IceCure has developed and markets the IceCure family of...